drugset / Trial / NCT03673020
Phase 1a Study to Evaluate Immunogenicity of ASV®
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label Phase 1a First-in-Human Study to determine Safety and Tolerability of ASV® AGEN2017 with QS-21 Stimulon® Adjuvant as a Single Agent in Subjects With Tumors at Risk of Relapse Undergoing Observation as Standard of Care Following Complete Surgical Resection.
Timeline
- Start
- 2019-05-16
- Primary completion
- 2021-02-03
- Completion
- 2021-02-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AGEN2017 | Vaccine | — | Subcutaneous |
| Background | QS-21 | Other / unclassified | — | Subcutaneous |